Breast cancer risk from using HRT is 'twice what was thought'
https://www.theguardian.com/science/2019/aug/29/breast-cancer-risk-from-using-hrt-is-twice-what-was-thought
Breast cancer risk from using HRT is twice what was thought
Sarah Boseley Health editor
Thu 29 Aug 2019 23.30 BST Last modified on Fri 30 Aug 2019 01.00 BST
The risk of breast cancer from using hormone replacement therapy is double what was previously thought, according to a major piece of research, which confirms that HRT is a direct cause of the cancer.
The findings of the definitive study will cause concern among the 1 million women in the UK and millions more around the world who are using HRT. It finds that the longer women take it, the greater their risk, with the possibility that just one year is risk-free. It also finds that the risk does not go away as soon as women stop taking it, as had been previously assumed.
(snip)
The research, published in the Lancet medical journal, says one in 50 women of average weight taking the most common form combined daily oestrogen and progestogen for five years will get breast cancer as a result.
That risk is twice what was thought, because it continues at some level for 10 or more years after women stop taking HRT. There are about 1 million women in the UK on HRT, 5 million in the rest of Europe and 6 million in the US.
The Medicines and Healthcare Products Regulatory Authority (MHRA) said women who are taking or have ever taken HRT should be vigilant and may want to talk to their doctor next time they have a routine appointment. They should ensure they go for breast screening.
(snip)
The paper, by the global Collaborative Group on Hormonal Factors in Breast Cancer, pulled together data from 58 studies around the world on more than 108,000 women who had developed breast cancer after taking menopausal hormone therapy (MHT) they say replacement therapy or HRT is a misnomer and a marketing description.
In western countries, 6.3% of women of average weight will develop breast cancer over the 20 years from the age of 50 without any hormone therapy. The study found that rose to 8.3% among women taking the most common hormonal combination oestrogen plus daily progestogen.
(snip)